UNSPSC 51201824: Betazole dihydrochloride

This classification denotes a diagnostic reagent with the molecular formula C5H9N3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 66ABP6C83F, chemically known as 3-(2-aminoethyl)pyrazole dihydrochloride, but more generally known as betazole dihydrochloride, which bears US NIH Compound Identifier 67412. European Medicines Agency schedules betazole dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05805MIG.

Most nations, for tariff purposes, schedule betazole dihydrochloride under HS 29331990. SMILES: C1C[NH]NC1CCN.CL.CL.

UNSPSC 51201824 Betazole dihydrochloride is a Commodity code, but the recent state and local activity under this code does not match the pharmaceutical ingredient named in the code. The Mississippi State Department of Health posted a sole source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with an objection deadline of August 3, 2026 — a vaccine product that falls outside the betazole dihydrochloride scope. The source shows no additional recent state and local opportunities tagged to this code, and no evidence of state or local procurement activity for betazole dihydrochloride itself.

The mismatch between the code's nominal pharmaceutical ingredient and the vaccine solicitation suggests either a tagging error in the source data or limited recent activity in the betazole dihydrochloride category among state and local buyers. No geographic concentration, issuing-body pattern, or representative opportunity pipeline can be established from a single unrelated Yellow Fever Vaccine notice. Business development professionals should verify whether this code aligns with their product offering or whether a different UNSPSC classification better reflects the goods or services being pursued.